Home / Learn / Precision Medicine / Immunotherapy / Immune-Related Adverse Events

Immune-Related Adverse Events

The Latest Resources

Members of the ACCC IO Institute Executive Committee discuss the importance of standardizing education for Immunotherapy patients and how designating a champion within your practice can play a critical role in the success of irAE identification and management.(features Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPH, FASHP)

  • Managing Dermatologic Adverse Events From Immunotherapy
    By Joshua Arbesman, MD

    Oncodermatology is a rapidly developing field that is attracting significant interest and generating new literature in the context of cancer treatment strategies.

  • Emergency Medicine Providers: Key Partners in the Acute Care of irAEs
    By Jason Bischof, MD

    The non-specific adverse events of immune-based therapies, which often mimic autoimmune disorders rather than traditional cytotoxic effects, pose a significant challenge to emergency medicine providers.

  • Working with Rheumatologists to Manage irAEs
    By Laura C. Capelli, MD, MHS

    Caring for patients experiencing toxicities from treatment with immune checkpoint inhibitors (ICIs) requires multidisciplinary input and coordination. Rheumatologists evaluate and treat patients experiencing a wide variety of immune-related adverse events (irAEs), including inflammatory arthritis, sicca syndrome, polymyalgia rheumatica, myositis, vasculitis, and scleroderma. It’s important for rheumatologists to know that these irAEs can vary significantly in their time of onset, severity, and treatment. Accurately diagnosing and treating rheumatic irAEs requires that providers obtain a tailored patient history and physical examination, since there are no definitive diagnostic laboratory tests for these complications. 

  • [Publication] IO Wallet Card
    Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.

From Oncology Issues

  • Virtual Toxicity Team Johns Hopkins University
    This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team.
  • A Focus on APPs
    Sibel Blau, MD
    While the number of oncology patients and survivors is increasing, the growth of medical oncologists has lagged behind, and advanced practice providers (APPs) play a critical role in filling this care gap.
  • Issues: Biosimilars are Overcoming Challenges of a Turbulent, Unfriendly Marketplace
    Blake McCreery-Cullifer, CPRP
    In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
  • Summit Explores Role of Oncology Advanced Practitioners in Equitable Cancer Care Delivery
    Learn the 10 feasible and impactful “how-tos” Summit participants identified within three domains—care coordination and communication, clinical trials, and acknowledging and mitigating implicit bias.
  • Collaborative Learning Workshops Explore Best Practices for Implementing Cancer Immunotherapies in the Community
  • The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma
    Robert A. Figlin, MD, FACP; Jocelyn Mohs, PharmD, BCOP; and Laura S. Wood, RN, MSN, OCN
    In 2019 the Association of Community Cancer Centers developed an education program to provide all members of the multidisciplinary care team knowledge and resources to help successfully integrate immunotherapies into the treatment of patients with RCC.
  • Management of Hospital Admissions for Checkpoint Inhibitor Immune-Related Adverse Events at a Regional Cancer Center
    Andrew Li, PharmD, and Michela Altergott, PharmD
    With the rise of immunotherapies, it is critical to ensure patient safety, as the toxicity profiles of immunotherapy agents are vastly different from traditional cytotoxic chemotherapies.
  • Education Interventions Improve Management of irAEs, Study Shows
    Matthew R. Zibelman, MD
    Since the approval of the programmed death-1 (PD-1) inhibitors pembrolizumab and nivolumab for the treatment of metastatic melanoma in 2014, the oncology community has seen a tidal wave of new approvals and indications for immunotherapies to treat cancer.
  • Highlights from a Virtual ASCO 2020
    Cary A. Presant, MD, FACP, FASCO
    Listed are my highlights of the ASCO 2020 abstracts, which were chosen if they were a practice-changing study or trial with important new advances.
  • Virtual Toxicity Team Cleveland Clinic
    This article explores how Cleveland Clinic is taking a unique approach to recruiting specialists outside the field of oncology to participate in immunotherapy multispecialty immune-related adverse events (irAE) tumor boards.
  • Virtual Toxicity Team Jefferson Health
    This article explores how Jefferson Health is taking a unique approach to recruiting specialists outside the field of oncology to participate in an Immuno-oncology Working Group.
  • Elevating Survivorship: Results from Two National Surveys
    In order to explore experiences and needs concerning cancer survivorship from both the provider and the patient perspectives, ACCC and NCCS partnered to field two online surveys to oncology providers and cancer survivors, respectively.
  • A Physician Champion Takes a Practice-Based Immunotherapy Program to the Next Level
    Tracy Virgilio, RN, MSN, OCN
    Early symptom management is key to improving quality of life for patients with cancer, and proactive monitoring delivers unparalleled survival advantage while decreasing emergency visits and admissions. However, immunotherapies require special attention and procedures. Sidney Kimmel Cancer Center earned a 2018 ACCC Innovator Award for their immunotherapy triage algorithms, which provide non-oncology physicians and nurses with the tools to manage IO patients and prevent unnecessary admissions.
  • Immuno-Oncology: Breaking Barriers, Exploring Solutions, Improving Patient Care
    The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
  • Best Practices for Implementing Cancer Immunotherapy in the Community
    The Association of Community Cancer Centers (ACCC) recently hosted live continuing medical education (CME)-certified learning workshops at two community cancer programs to review current barriers to immunotherapy implementation in the community setting. During the workshops, an expert faculty panel engaged participants in discussion on the challenges that they may face as they integrate immunotherapy into their clinical practice, as well as practical solutions and strategies they can apply to overcome these barriers. This article summarizes the guidance and information provided by the faculty on the various issues raised during the workshop discussions.
  • Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.
  • Turning on the Light Switch
    By Ann McGreal, RN
    Discover how 2017 ACCC Innovator Award winner Advocate Medical Group developed and implemented an immunotherapy program, lessons learned, and tools created to educate staff and patients.
  • Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  • Real-World Experiences in Immunotherapy Delivery
    The ACCC education project, “Real-World Experiences in Immunotherapy Delivery,” addresses some of the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.
  • Advancing Immuno-Oncology in the Community Setting
    Steven Powell, MD
    As cancer treatment evolves with the emergence of genomics, personalized therapies, and immunotherapies, care delivery must also transform.
Toxicity Team Article

On-Demand Webinars

  • Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.

Blog Posts


  • Expanding Access to Bispecific Antibodies in Community Cancer Care
    August 03, 2022
    Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.
  • Micro Inmunoterapia_ACCCBuzz
    ACCC Tools for Immuno-Oncology Survivorship Care
    June 03, 2022
    In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.
    The Best (and Worst) of 2020
    December 30, 2020
  • Sigrun Hallmeyer pic
    June Is Cancer Immunotherapy Month
    June 25, 2020
    In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.